HIV-1 Vpu抑制剂BIT225联合三药抗逆转录病毒治疗对炎症与免疫细胞的调节作用
一项在泰国开展的II期试验纳入36例未治疗HIV-1感染者,随机接受标准三药方案(替诺福韦/恩曲他滨/依非韦伦)联合BIT225 100mg或200mg或安慰剂治疗12周。BIT225联合ART总体安全耐受,抗病毒疗效与单用ART相当;BIT225组可溶性CD163显著下降,活化CD4+、CD8+ T细胞、NK细胞及IL-21升高。
要点
- BIT225联合标准ART安全耐受,抗病毒疗效与单用ART相当
- BIT225组可溶性CD163(单核/巨噬细胞炎症标志物)显著下降
- BIT225组活化CD4+、CD8+ T细胞、NK细胞及IL-21升高
核心结论
- BIT225联合三药ART总体安全耐受,抗病毒疗效与单用ART相当。
- BIT225可显著降低可溶性CD163并增加活化T细胞、NK细胞及IL-21,提示对炎症和免疫功能的调节作用。
研究设计与样本
- II期试验在泰国纳入36例HIV-1感染、未接受治疗参与者。
- 受试者接受标准ART(替诺福韦酯/恩曲他滨/依非韦伦)联合BIT225 100mg或200mg或安慰剂,每日一次,共12周。
主要发现
- BIT225联合ART总体安全且耐受良好,抗病毒疗效与单用ART相当。
- 次要终点可溶性CD163在BIT225组显著下降。
- 血浆来源活化CD4+和CD8+ T细胞、自然杀伤细胞及白细胞介素21在BIT225治疗者中升高。
临床怎么用
- BIT225联合标准ART未显示抗病毒疗效优于单用ART,但可调节单核/巨噬细胞炎症标志物及免疫细胞活化。
- 需进一步临床研究在未治疗及经治人群中确认并扩展上述发现。
局限性
- 样本量较小(36例),随访12周,仅探索性分析炎症与免疫指标。
- 原文未报告具体数值、统计显著性阈值及两组剂量间比较结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BIT225 is a first-in-class inhibitor of human immunodeficiency virus (HIV) type 1 Vpu. A phase II trial enrolled 36 HIV-1-infected, treatment-naive participants in Thailand to receive standard-of-care antiretroviral therapy (ART), tenofovir disoproxil fumarate/emtricitabine/efavirenz (Atripla), with 100 or 200 mg of BIT225 or placebo (daily) for 12 weeks. Combined treatment with BIT225 and ART was found to be generally safe and well tolerated, with antiviral efficacy comparable to that of ART alone. The secondary end point-soluble CD163, a marker of monocyte/macrophage inflammation-was noted to be significantly decreased in the BIT225 arm. Plasma-derived activated CD4+ and CD8+ T cells, natural killer cells, and interleukin 21 were increased in those treated with BIT225. These findings are consistent with inhibition of the known effects of HIV Vpu and may reflect clinically important modulation of inflammatory and immune function. Further clinical study is planned to both confirm and extend these important findings in treatment-naive, and treatment-experienced individuals. Clinical Trials Registration. Australian New Zealand Clinical Trials Registry (Universal Trial Number U1111-1191-2194).
引用
- Luscombe CA, Avihingsanon A, Supparatpinyo K, et al. Human Immunodeficiency Virus Type 1 Vpu Inhibitor, BIT225, in Combination with 3-Drug Antiretroviral Therapy: Inflammation and Immune Cell Modulation. J Infect Dis. 2021. PMID: 33038249. doi:10.1093/infdis/jiaa635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。